Abstract
BackgroundCheckpoint inhibitors have changed the outcomes for patients with advanced melanoma. However, many patients still show primary resistance to single-agent therapy. Recently, the role of the gut microbiome in influencing...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have